For the Inventor, By the Inventor

Enter inventor name

Russell Thomas

USPTO Granted Patents = 17 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 6.3

ph-index = 5

Forward Citations = 47(Granted Patents)

Location History:

Bresso, IT (2023)
Siena, IT (2007 - 2024)

Company Filing History:

Merck Serono S. A.

University of Texas System

Golgi Neurosciences S.r.l.

Elixir Pharmaceuticals, Inc.

5. 1 out of 156

Applied Research Systems Ars Holding N.v.

Rodin Therapeutics, Inc.

Breye Therapeutics Aps

Aop Orphan Pharmaceuticals Ag

10. 1 out of 11

Siena Biotech S.p.a.

11. 1 out of 40

Laboratoires Serono S.a.

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

Loading Chart...

17 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12258337 - Bicyclic CX3CR1 receptor agonists (2025-03-25),

2. 11958839 - Bicyclic CX3CR1 receptor agonists (2024-04-16),

3. 11623919 - Heterocyclic P2X7 antagonists (2023-04-11),

4. 11597702 - Substituted pyrazoles FFA4/GPR120 receptor agonists (2023-03-07),

5. 11155538 - Bicyclic CX3CR1 receptor agonists (2021-10-26),

6. 10329254 - Process for the preparation of 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide and intermediates thereof (2019-06-25),

7. 9981920 - Inhibitors of histone deacetylase (2018-05-29),

8. 8946227 - Piperazine derivatives and methods of use (2015-02-03),

9. 8592463 - Hedgehog pathway antagonists and therapeutic applications thereof (2013-11-26),

10. 8486990 - SirT inhibitors that bind to NAD (2013-07-16),

11. 8415480 - Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor (2013-04-09),

12. 8404690 - Piperazine-2-carboxamide derivatives (2013-03-26),

13. 7897765 - Therapeutic compounds and uses thereof (2011-03-01),

14. 7855212 - Pyridinyl acetonitriles (2010-12-21),

15. 7754722 - Piperazine derivatives and methods of use (2010-07-13),

Title: Innovator Spotlight: Russell Thomas

Introduction: Russell Thomas, based in Siena, Italy, is an accomplished inventor with an impressive portfolio of 17 patents. His contributions to the field of pharmaceuticals, particularly related to receptor activity in humans, reflect a deep commitment to advancing medical science.

Latest Patents: Among his latest innovations are patents focused on Bicyclic CX3CR1 receptor agonists. These patents disclose novel cycloalka[b]heteroaryl compounds that possess CX3CR1/fractalkine receptor agonistic properties. The patents detail pharmaceutical compositions that include these compounds, outline chemical processes for their preparation, and explore their therapeutic uses in treating or preventing diseases associated with CX3CR1 receptor activity in both animals and humans.

Career Highlights: Throughout his career, Russell has made significant strides in research and development, particularly in the pharmaceutical industry. He has worked with esteemed organizations such as Merck Serono S.A. and the University of Texas System, where he leveraged his expertise to contribute to groundbreaking advancements in drug discovery and development.

Collaborations: Russell has collaborated with notable colleagues in his field, including Matthias Schwarz and Paolo Pevarello. These collaborations have helped foster innovation and drive impactful research outcomes, showcasing the importance of teamwork in scientific endeavors.

Conclusion: Russell Thomas stands out as a leading inventor in the pharmaceutical realm. His dedication to innovation is evident in his numerous patents and collaborative efforts, ultimately contributing to advancements that can greatly benefit public health. His work exemplifies the vital role of inventors in transforming scientific ideas into practical solutions for modern challenges.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…